samedan logo
home > pmps > autumn 2021 > considerations for improving patient compliance with superior suspensions
Pharmaceutical Manufacturing and Packing Sourcer

Considerations for Improving Patient Compliance With Superior Suspensions

Poor medication compliance results in 50% of treatment failures each year – and adds billions to global healthcare expenditures (1). What is one of the leading causes behind poor compliance? Certain populations, such as children and the elderly, require drug formats other than traditional tablets and capsules, due to their difficulty swallowing.

That’s where sensory enhancement of the drug experience comes into play. In general, creating better designed drugs and more delivery options improves the likelihood that patients will take their medications as prescribed. Chewable tablets, orally disintegrating tablets, and liquid formulations are all delivery formats that are easier for patients to take, and, therefore, aid in greater rates of patient compliance.

Liquid and semi-liquid drugs offer an alternative, customisable vehicle for drug delivery among populations with low patient compliance. Both solutions and suspensions are two key formats that fall within the liquid/semi-liquid drug category.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
Shawn Branning has been with IFF (previously DuPont Nutrition & Biosciences) for five years, serving in various positions related to strategic growth in the Pharmaceutical Solutions and Nourish businesses. In addition to a business background with an MBA in Marketing, Shawn has a strong technical background – having served as an R&D chemist from 2002-2008 with multiple patents and an MS Chemistry from Lehigh University, US. As the Global Strategic Marketing Manager for Novel Pharma, Shawn Branning is responsible for the future growth and expansion into advanced drug delivery. On top of new product developments, his responsibilities include joint ventures and evaluation of M&A opportunities.
Print this page
Send to a friend
Privacy statement
News and Press Releases


OXFORD, England, 22nd September - Owen Mumford Pharmaceutical Services, a division of Owen Mumford Ltd. has launched its new Aidaptus® auto-injector platform following successful completion of development.
More info >>

White Papers



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement